DE69812177T2 - 3'-epi k-252a derivate - Google Patents

3'-epi k-252a derivate Download PDF

Info

Publication number
DE69812177T2
DE69812177T2 DE69812177T DE69812177T DE69812177T2 DE 69812177 T2 DE69812177 T2 DE 69812177T2 DE 69812177 T DE69812177 T DE 69812177T DE 69812177 T DE69812177 T DE 69812177T DE 69812177 T2 DE69812177 T2 DE 69812177T2
Authority
DE
Germany
Prior art keywords
epi
derivatives
compounds
survival
enhancement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69812177T
Other languages
German (de)
English (en)
Other versions
DE69812177D1 (de
Inventor
L Hudkins
E Gingrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Cephalon LLC
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Cephalon LLC filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of DE69812177D1 publication Critical patent/DE69812177D1/de
Publication of DE69812177T2 publication Critical patent/DE69812177T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE69812177T 1997-12-31 1998-12-30 3'-epi k-252a derivate Expired - Lifetime DE69812177T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7026397P 1997-12-31 1997-12-31
PCT/US1998/027644 WO1999033836A1 (en) 1997-12-31 1998-12-30 3'-epimeric k-252a derivatives

Publications (2)

Publication Number Publication Date
DE69812177D1 DE69812177D1 (de) 2003-04-17
DE69812177T2 true DE69812177T2 (de) 2004-01-15

Family

ID=22094212

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69812177T Expired - Lifetime DE69812177T2 (de) 1997-12-31 1998-12-30 3'-epi k-252a derivate

Country Status (15)

Country Link
US (2) US6093713A (enExample)
EP (1) EP1044203B1 (enExample)
JP (1) JP4405667B2 (enExample)
KR (1) KR20010033737A (enExample)
CN (1) CN1285836A (enExample)
AT (1) ATE234308T1 (enExample)
AU (1) AU1947499A (enExample)
BR (1) BR9814543A (enExample)
CA (1) CA2315953C (enExample)
DE (1) DE69812177T2 (enExample)
DK (1) DK1044203T3 (enExample)
ES (1) ES2194385T3 (enExample)
NO (1) NO20003397L (enExample)
PT (1) PT1044203E (enExample)
WO (1) WO1999033836A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2275373C2 (ru) * 2000-12-08 2006-04-27 Орто-Макнейл Фармасьютикал, Инк. Макрогетероциклические соединения
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
DE60212836T2 (de) * 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
DE10161940A1 (de) * 2001-12-17 2003-07-03 Nad Ag N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
US6723844B1 (en) * 2003-02-27 2004-04-20 Abbott Laboratories Preparation of K-252a
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
EP2124554B1 (en) * 2006-12-14 2012-02-08 Tautatis, Inc. Compositions and methods for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155284A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
WO1988007045A1 (fr) * 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
WO1994027982A1 (en) 1993-05-28 1994-12-08 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5585488A (en) * 1994-07-04 1996-12-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing indolocarbazole derivatives
WO1997005140A1 (en) 1995-07-31 1997-02-13 Novartis Ag Trindene compounds
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis

Also Published As

Publication number Publication date
NO20003397L (no) 2000-08-31
AU1947499A (en) 1999-07-19
US6093713A (en) 2000-07-25
CA2315953C (en) 2010-11-09
WO1999033836A1 (en) 1999-07-08
JP2001527079A (ja) 2001-12-25
PT1044203E (pt) 2003-07-31
CN1285836A (zh) 2001-02-28
KR20010033737A (ko) 2001-04-25
ES2194385T3 (es) 2003-11-16
WO1999033836A9 (en) 2000-09-14
DK1044203T3 (da) 2003-07-14
NO20003397D0 (no) 2000-06-29
JP4405667B2 (ja) 2010-01-27
CA2315953A1 (en) 1999-07-08
ATE234308T1 (de) 2003-03-15
EP1044203B1 (en) 2003-03-12
EP1044203A1 (en) 2000-10-18
BR9814543A (pt) 2000-10-10
DE69812177D1 (de) 2003-04-17
US6451786B1 (en) 2002-09-17

Similar Documents

Publication Publication Date Title
CU23126A3 (es) Inhibicion de kinasa raf usando ureas heterociclicas sustituidas
TR200000151T2 (tr) Yeni bileşimler.
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
NO962059L (no) Antiarytmiske benzodiazepiner
ES2193252T3 (es) Quinolonas y su uso terapeutico.
WO1999057117A3 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
DE69627411D1 (de) Triazinderivate, ihre Herstellung und Verwendung
ATE216871T1 (de) Derivate des pyrazolo-(1,5-a)-pyrimidine, dessen herstellung und haarfärbemittel mit solchen derivaten
MX9603479A (es) Derivados de 4-amino de acido micofenolico con actividad inmunosupresora.
FI971953L (fi) Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6-aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit
DE69623472D1 (de) Derivate von dolastatin, dreen herstellung un verwendung
DE69622871D1 (de) Tetralin-verbindungen mit multi-drugresistenz (mdr)-aktivitat
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
ATE242234T1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
DE69715010D1 (de) Ausgewählte k-252a derivate
ATE234308T1 (de) 3'-epi k-252a derivate
DE69322750D1 (de) Dibekacin und Arbekacin Derivate wirksam gegen resistente Bakterien, und ihre Herstellung
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
DE69623819D1 (de) Furan- und thiophencarbothioamid derivate, deren herstellung und deren verwendung als inhibitoren der replikation von hiv-1 und hiv-1 mutanten
NO991734L (no) Pyrazolinoner for behandling av potensforstyrrelser
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
SU1786802A1 (ru) 2,4-ДИМЕТИЛ-9-ОКСИПИРИДО[1,2-a]ПИРИМИДИНИЙХЛОРИД, ОБЛАДАЮЩИЙ АНТИДЕПРЕССИВНОЙ АКТИВНОСТЬЮ

Legal Events

Date Code Title Description
8364 No opposition during term of opposition